Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "infections"

299 News Found

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
News | February 17, 2025

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified


Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study
Clinical Trials | February 03, 2025

Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study

Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years


Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
Clinical Trials | January 13, 2025

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure


HMPV update: States advised to strengthen awareness among masses regarding preventive measures
Healthcare | January 08, 2025

HMPV update: States advised to strengthen awareness among masses regarding preventive measures

Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country


CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Drug Approval | January 05, 2025

CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia

Wockhardt plans to launch Miqnaf in the Indian market in coming few months


Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova
Drug Approval | January 01, 2025

Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova

Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026


Schizophrenia in Children: Understanding Early-Onset Schizophrenia
News | December 31, 2024

Schizophrenia in Children: Understanding Early-Onset Schizophrenia

Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia


New method for detecting H. pylori and its mutations can help dyspeptic patients in resource poor remote settings: PIB
News | December 28, 2024

New method for detecting H. pylori and its mutations can help dyspeptic patients in resource poor remote settings: PIB

Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders


Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
News | December 20, 2024

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery